McKesson (NYSE:MCK) will be posting its quarterly earnings results before the market opens on Thursday, October 25th. Analysts expect McKesson to post earnings of $3.27 per share for the quarter. McKesson has set its FY19 guidance at $13.00 to $13.80 EPS.
McKesson (NYSE:MCK) last posted its quarterly earnings data on Thursday, July 26th. The company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.89 by $0.01. The firm had revenue of $52.61 billion during the quarter, compared to analyst estimates of $52.91 billion. McKesson had a negative net margin of 0.18% and a positive return on equity of 25.19%. McKesson’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.47 EPS. On average, analysts expect McKesson to post $13 EPS for the current fiscal year and $14 EPS for the next fiscal year.
NYSE MCK opened at $135.04 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.00 and a quick ratio of 0.57. The company has a market cap of $26.50 billion, a P/E ratio of 10.70, a PEG ratio of 1.42 and a beta of 1.23. McKesson has a 52 week low of $122.49 and a 52 week high of $178.86.
The company also recently disclosed a quarterly dividend, which was paid on Monday, October 1st. Investors of record on Tuesday, September 4th were paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 1.16%. The ex-dividend date of this dividend was Friday, August 31st. This is a positive change from McKesson’s previous quarterly dividend of $0.34. McKesson’s payout ratio is 12.36%.
In other McKesson news, Director N Anthony Coles sold 1,350 shares of the company’s stock in a transaction that occurred on Friday, August 31st. The shares were sold at an average price of $128.69, for a total transaction of $173,731.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.87% of the company’s stock.
Several research analysts recently commented on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $160.00 price objective on shares of McKesson in a research note on Friday, July 27th. Robert W. Baird lowered shares of McKesson from an “outperform” rating to a “neutral” rating in a research note on Friday, July 20th. Royal Bank of Canada cut their price target on shares of McKesson to $158.00 and set a “market perform” rating on the stock in a research note on Friday, June 29th. Citigroup cut their price target on shares of McKesson from $160.00 to $2.86 and set a “buy” rating on the stock in a research note on Friday, July 20th. Finally, Mizuho restated a “hold” rating and set a $133.00 price target on shares of McKesson in a research note on Sunday, August 12th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the company’s stock. McKesson presently has an average rating of “Hold” and an average target price of $151.99.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Read More: Why investors pay attention to retained earnings
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.